Refractory Anemia with Ring Sideroblasts (RARS) and RARS with Thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management"

Overview

Journal Am J Hematol

Specialty Hematology

Date 2019 Jan 9

PMID 30618061

Citations 12

Authors

Mrinal M Patnaik

Ayalew Tefferi

Affiliations

Soon will be listed here.

Abstract

Disease Overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS-RS) and RARS with thrombocytosis (RARS-T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T).

Diagnosis: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN-RS-T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS-RS-SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes.

Mutations And Karyotype: Mutations in SF3B1 are seen in ≥80% of patients with MDS-RS-SLD and MDS/MPN-RS-T, and strongly correlate with the presence of BM RS; MDS/MPN-RS-T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both.

Risk Stratification: Most patients with MDS-RS-SLD are stratified into lower-risk groups by the revised-IPSS. Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation.

Treatment: Anemia and iron overload are complications seen in both and are managed similar to lower-risk MDS and MPN. The advent of luspatercept, a first-in-class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN-RS-T, especially in the presence of JAK2V617F, but the value of platelet-lowering drugs remains uncertain.

Citing Articles

ATP-Binding Cassette Transporter of Clinical Significance: Sideroblastic Anemia.

Ogunbileje J, Harris N, Wynn T, Kashif R, Stover B, Osa-Andrews B J Pers Med. 2024; 14(6).

PMID: 38929857 PMC: 11204910. DOI: 10.3390/jpm14060636.

Abnormal mitochondrial iron metabolism damages alveolar type II epithelial cells involved in bleomycin-induced pulmonary fibrosis.

Shao M, Cheng H, Li X, Qiu Y, Zhang Y, Chang Y Theranostics. 2024; 14(7):2687-2705.

PMID: 38773980 PMC: 11103499. DOI: 10.7150/thno.94072.

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.

Li F, Qin T, Li B, Qu S, Pan L, Zhang P Leukemia. 2024; 38(6):1334-1341.

PMID: 38714876 PMC: 11147759. DOI: 10.1038/s41375-024-02262-2.

Myelodysplastic syndrome with IgG4‑related disease: A case report.

Wang L, Pang X, Hong Z, Ye B, Hu Z, Zhang C Oncol Lett. 2024; 27(4):166.

PMID: 38426159 PMC: 10902754. DOI: 10.3892/ol.2024.14299.

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process.

Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W Front Oncol. 2023; 13:1116438.

PMID: 37007111 PMC: 10063959. DOI: 10.3389/fonc.2023.1116438.

References

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D . Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15):1384-95. PMC: 3322589. DOI: 10.1056/NEJMoa1103283. View

Levi S, Corsi B, Bosisio M, Invernizzi R, Volz A, Sanford D . A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem. 2001; 276(27):24437-40. DOI: 10.1074/jbc.C100141200. View

Malcovati L, Germing U, Kuendgen A, Della Porta M, Pascutto C, Invernizzi R . Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-10. DOI: 10.1200/JCO.2006.08.5696. View

Germing U, Gattermann N, Strupp C, Aivado M, Aul C . Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000; 24(12):983-92. DOI: 10.1016/s0145-2126(00)00088-6. View

Greenberg P, Rigsby C, Stone R, Deeg H, Gore S, Millenson M . NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2010; 7 Suppl 9:S1-16. DOI: 10.6004/jnccn.2009.0082. View

Patnaik M, Hanson C, Sulai N, Hodnefield J, Knudson R, Ketterling R . Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674-7. DOI: 10.1182/blood-2012-03-415356. View

Silverman L, Demakos E, Peterson B, Kornblith A, Holland J, Odchimar-Reissig R . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-40. DOI: 10.1200/JCO.2002.04.117. View

List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D . Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352(6):549-57. DOI: 10.1056/NEJMoa041668. View

Gabrilove J, Paquette R, Lyons R, Mushtaq C, Sekeres M, Tomita D . Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008; 142(3):379-93. PMC: 2654479. DOI: 10.1111/j.1365-2141.2008.07181.x. View

10.

Patnaik M, Lasho T, Finke C, Hanson C, Hodnefield J, Knudson R . Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013; 88(3):201-6. DOI: 10.1002/ajh.23373. View

11.

Cotter P, Baumann M, Bishop D . Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A. 1992; 89(9):4028-32. PMC: 525625. DOI: 10.1073/pnas.89.9.4028. View

12.

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, cermak J, Del Canizo C . Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-64. PMC: 3811170. DOI: 10.1182/blood-2013-03-492884. View

13.

Garcia-Manero G . Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014; 89(1):97-108. DOI: 10.1002/ajh.23642. View

14.

Guernsey D, Jiang H, Campagna D, Evans S, Ferguson M, Kellogg M . Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009; 41(6):651-3. DOI: 10.1038/ng.359. View

15.

Cazzola M, Della Porta M, Malcovati L . The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021-34. PMC: 3862275. DOI: 10.1182/blood-2013-09-381665. View

16.

Tefferi A, Al-Kali A, Begna K, Patnaik M, Lasho T, Rizo A . Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016; 6:e405. PMC: 4817097. DOI: 10.1038/bcj.2016.13. View

17.

Tefferi A, Gangat N, Mudireddy M, Lasho T, Finke C, Begna K . Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clin Proc. 2018; 93(10):1363-1374. DOI: 10.1016/j.mayocp.2018.04.013. View

18.

Mangaonkar A, Lasho T, Finke C, Gangat N, Al-Kali A, Elliott M . Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer J. 2018; 8(2):18. PMC: 5809387. DOI: 10.1038/s41408-018-0051-1. View

19.

Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F . Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332(17):1132-6. DOI: 10.1056/NEJM199504273321704. View

20.

Wang L, Lawrence M, Wan Y, Stojanov P, Sougnez C, Stevenson K . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26):2497-506. PMC: 3685413. DOI: 10.1056/NEJMoa1109016. View